Get started
Author

Suresh K Komati

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
2018 · Ralf Reilmann, Andrew McGarry, et al. · The Lancet Neurology · 111
Clinical manifestations of intermediate allele carriers in Huntington disease
2016 · Esther Cubo, María A. Ramos-Arroyo, et al. · Neurology · 53
Reduced Cancer Incidence in Huntington’s Disease: Analysis in the Registry Study
2018 · Paul McNulty, Richard Pilcher, et al. · Journal of Huntington s Disease · 35
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study
2024 · Ralf Reilmann, Karen E Anderson, et al. · The Lancet Neurology · 34
PDF
Meaningful and Measurable Health Domains in Huntington’s Disease: Large-Scale Validation of the Huntington’s Disease Health-Related Quality of Life Questionnaire Across Severity Stages
2019 · Aileen K. Ho, Mike C. Horton, et al. · Value in Health · 9
G001 2023 UK national audit of predictive testing for Huntington’s disease
2024 · Nayana Lahiri, Lauren Limb, et al.
PDF
F15 Is there a correlation between age of onset of symptoms and number of cag repeats in patients with juvenile and younger onset huntington’s disease? a study of 27 patients in the north east of england
2018 · Sharon McDonnell, Joe Thorne, et al.
Works count: 7
Citation count: 242
H-index: 5
I10-index: 4
Year
Topic
Type